Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 27;17(10):1281.
doi: 10.3390/ph17101281.

Ischemic Optic Neuropathy: A Review of Current and Potential Future Pharmacotherapies

Omar Badla  1   2 , Beshr Abdulaziz Badla  3 , Amr Almobayed  1   2 , Carlos Mendoza  1 , Krishna Kishor  1   2 , Sanjoy K Bhattacharya  1   2   4
Affiliations
Review

Ischemic Optic Neuropathy: A Review of Current and Potential Future Pharmacotherapies

Omar Badla et al. Pharmaceuticals (Basel). .

Abstract

The treatment of arteritic anterior ischemic optic neuropathy (AAION), non-arteritic ischemic optic neuropathy (NAAION), and posterior ischemic optic neuropathy (PION) is a topic of ongoing research with mixed evidence on some pharmacotherapies and a need for more consensus. This manuscript provides an overview of these conditions' current, potential future, and attempted pharmacotherapies. AAION's current treatment regimen consists of high-dose steroids, with methotrexate, tocilizumab, and abatacept, being the most viable steroid-sparing therapy candidates. As for NAAION, the treatments being tried are vast, with mixed evidence supporting each modality. Similarly, despite the various treatment options explored, there still needs to be a universally effective therapy for PION. More research is needed to formulate an agreed-upon treatment regimen for these conditions.

Keywords: AAION; AION; ION; NAAION; NAION; PION; ischemic optic neuropathy; management; pharmacotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The subtypes of AION and PION. Created with Biorender.com.
See this image and copyright information in PMC

References

    1. Salvetat M.L., Pellegrini F., Spadea L., Salati C., Zeppieri M. Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION): A Comprehensive Overview. Vision. 2023;7:72. doi: 10.3390/vision7040072. - DOI - PMC - PubMed
    1. Hayreh S.S. Ischemic optic neuropathy. Prog. Retin. Eye Res. 2009;28:34–62. doi: 10.1016/j.preteyeres.2008.11.002. - DOI - PubMed
    1. Zhao F.F., Chen Y., Li T.P., Wang Y., Lin H.J., Yang J.F., Chen L., Tan S.Y., Liang J.J., Cen L.P. Visual outcome of various dose of glucocorticoids treatment in nonarteritic anterior ischemic optic neuropathy—A retrospective analysis. BMC Ophthalmol. 2024;24:100. doi: 10.1186/s12886-024-03354-4. - DOI - PMC - PubMed
    1. Lantos K., Dömötör Z.R., Farkas N., Kiss S., Szakács Z., Garami A., Varga G., Lujber L., Kanaan R., Hegyi P., et al. Efficacy of Treatments in Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health. 2022;19:2718. doi: 10.3390/ijerph19052718. - DOI - PMC - PubMed
    1. Huang T.L., Wen Y.T., Chang C.H., Chang S.W., Lin K.H., Tsai R.K. Early Methylprednisolone Treatment Can Stabilize the Blood-Optic Nerve Barrier in a Rat Model of Anterior Ischemic Optic Neuropathy (rAION) Investig. Ophthalmol. Vis. Sci. 2017;58:1628–1636. doi: 10.1167/iovs.16-21017. - DOI - PubMed

LinkOut - more resources